The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.

Toni Portis*, Lori Cooper, Patrick Dennis, Richard M Longnecker

*Corresponding author for this work

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

Most adults are infected with Epstein-Barr virus (EBV), a virus that establishes a lifelong latent infection in B lymphocytes and is associated with a variety of cancers. In normal individuals, latent infection with EBV typically poses no health risk, but upon immunosuppression, either following organ transplantation or HIV infection, malignancies and lymphoproliferative diseases can result. We have utilized both transgenic mice and EBV transformed lymphoblastoid cell lines (LCLs) as models of EBV latent infection to explore the function of latent membrane protein 2A (LMP2A) of EBV. This has allowed us to identify important functional domains of LMP2A, essential host proteins necessary for LMP2A function, and the effect of LMP2A on normal B cell function. These studies have provided a more complete understanding of the role of LMP2A in EBV latency and tumorigenesis and may allow for the identification of novel therapeutics for the treatment or eradication of EBV latent infections and associated proliferative disorders.

Original languageEnglish (US)
JournalFrontiers in bioscience : a journal and virtual library
Volume7
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.'. Together they form a unique fingerprint.

  • Cite this